Vaccines against Human Respiratory Syncytial Virus

Perspectives in Medical Virology

Volumn 14, Issue , 2006, Pages 233-278

  Collins, Peter L ^a   Murphy, Brian R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750908772     PISSN: 01687069     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0168-7069(06)14008-2     Document Type: Review

References (182)

1. American Academy of Pediatrics, C. O. I. D. A. C. O. F. A. N. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 1996; 97: 137.
2. American Academy of Pediatrics, C. O. I. D. A. C. O. F. A. N. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112: 1442.
3. Bartholdy C., Olszewska W., Stryhn A., Thomsen A.R., and Openshaw P.J. Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis. J Gen Virol 85 (2004) 3017
4. Bartlett E.J., Amaro-Carambot E., Surman S.R., Newman J.T., Collins P.L., Murphy B.R., and Skiadopoulos M.H. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine 23 (2005) 4631
5. Bastien N., Taylor G., Thomas L.H., Wyld S.G., Simard C., and Trudel M. Immunization with a peptide derived from the G glycoprotein of bovine respiratory syncytial virus (BRSV) reduces the incidence of BRSV-associated pneumonia in the natural host. Vaccine 15 (1997) 1385
6. Bastien N., Trudel M., and Simard C. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine 17 (1999) 832
7. Beeler J.A., and Van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63 (1989) 2941
8. Belanger H., Fleysh N., Cox S., Bartman G., Deka D., Trudel M., Koprowski H., and Yusibov V. Human respiratory syncytial virus vaccine antigen produced in plants. FASEB J 14 (2000) 2323
9. Belshe R.B., Anderson E.L., and Walsh E.E. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 168 (1993) 1024
10. Belshe R.B., Newman F.K., Anderson E.L., Wright P.F., Karron R.A., Tollefson S., Henderson F.W., Meissner H.C., Madhi S., Roberton D., Marshall H., Loh R., Sly P., Murphy B., Tatem J.M., Randolph V., Hackell J., Gruber W., and Tsai T.F. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis 190 (2004) 2096
11. Belshe R.B., Van Voris L.P., and Mufson M.A. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis 145 (1982) 311
12. Bembridge G.P., Rodriguez N., Garcia-Beato R., Nicolson C., Melero J.A., and Taylor G. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J Gen Virol 81 (2000) 2519
13. Bembridge G.P., Rodriguez N., Garcia-Beato R., Nicolson C., Melero J.A., and Taylor G. Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine 19 (2000) 1038
14. Bermingham A., and Collins P.L. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci USA 96 (1999) 11259
15. Biacchesi S., Pham Q.N., Skiadopoulos M.H., Murphy B.R., Collins P.L., and Buchholz U.J. Infection of non-human primates with recombinant human metapneumovirus lacking the SH, G or M2-2 protein catagorizes each as a nonessential accessory protein and identifies a vaccine candidate. J Virol 79 (2005) 12608
16. Biacchesi S., Skiadopoulos M.H., Tran K.C., Murphy B.R., Collins P.L., and Buchholz U.J. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology 321 (2004) 247
17. Blanco J.C., Boukhvalova M.S., Hemming P., Ottolini M.G., and Prince G.A. Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection. Expert Rev Anti Infect Ther 3 (2005) 945
18. Buchholz U.J., Granzow H., Schuldt K., Whitehead S.S., Murphy B.R., and Collins P.L. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. J Virol 74 (2000) 1187
19. Cano F., Plotnicky-Gilquin H., Nguyen T.N., Liljeqvist S., Samuelson P., Bonnefoy J., Stahl S., and Robert A. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface- displayed RSV-peptides. Vaccine 18 (2000) 2743
20. Centers for Disease Control and Prevention, United States. Recommended childhood and adolescent immunization schedule, 2006. www.immunize.org/cdc/child.
21. Chen M., Hu K.F., Rozell B., Orvell C., Morein B., and Liljestrom P. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol 169 (2002) 3208
22. Coates H.V., Alling D.W., and Chanock R.M. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 83 (1966) 299
23. Collins PL, Chanock RM, Murphy BR. Respiratory syncytial virus. In: Fields Virology (Knipe DM, Howley PM, editors). 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2001.
24. Collins P.L., Hill M.G., Camargo E., Grosfeld H., Chanock R.M., and Murphy B.R. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci USA 92 (1995) 11563
25. Collins P.L., Hill M.G., and Johnson P.R. The two open reading frames of the 22 K mRNA of human respiratory syncytial virus: sequence comparison of antigenic subgroups A and B and expression in vitro. J Gen Virol 71 Pt 12 (1990) 3015
26. Collins P.L., Prince G.A., Camargo E., Purcell R.H., Chanock R.M., Murphy B.R., Davis A.R., Lubeck M.D., Mizutani S., and Hung P.P. Evaluation of the protective efficacy of recombinant vaccinia viruses and adenoviruses that express respiratory syncytial virus glycoproteins. In: Brown F., Chanock R.M., Ginsberg H.S., and Lerner R.A. (Eds). Vaccines 90 (1990), Cold Spring Harbor Laboratory Press, New York
27. Collins P.L., Purcell R.H., London W.T., Lawrence L.A., Chanock R.M., and Murphy B.R. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 8 (1990) 164
28. Connors M., Collins P.L., Firestone C.Y., and Murphy B.R. Respiratory syncytial virus (RSV) F, G, M2 (22 K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol 65 (1991) 1634
29. Connors M., Collins P.L., Firestone C.Y., Sotnikov A.V., Waitze A., Davis A.R., Hung P.P., Chanock R.M., and Murphy B.R. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10 (1992) 475
30. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse H.C.R., and Murphy B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 68 (1994) 5321
31. Connors M., Kulkarni A.B., Firestone C.Y., Holmes K.L., Morse H.C.D., Sotnikov A.V., and Murphy B.R. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+T cells. J Virol 66 (1992) 7444
32. Crowe Jr. J.E. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO programme for vaccine development. Vaccine 13 (1995) 415
33. Crowe Jr. J.E., Bui P.T., Davis A.R., Chanock R.M., and Murphy B.R. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12 (1994) 783
34. Crowe Jr. J.E., Bui P.T., London W.T., Davis A.R., Hung P.P., Chanock R.M., and Murphy B.R. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12 (1994) 691
35. Crowe Jr. J.E., Bui P.T., Siber G.R., Elkins W.R., Chanock R.M., and Murphy B.R. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 13 (1995) 847
36. Crowe Jr. J.E., Collins P.L., London W.T., Chanock R.M., and Murphy B.R. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 11 (1993) 1395
37. Crowe Jr. J.E., Firestone C.Y., and Murphy B.R. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 167 (2001) 3910
38. Crowe Jr. J.E., and Williams J.V. Immunology of viral respiratory tract infection in infancy. Paediatr Respir Rev 4 (2003) 112
39. De Swart R.L., Kuiken T., Timmerman H.H., Amerongen Gv G., Van Den Hoogen B.G., Vos H.W., Neijens H.J., Andeweg A.C., and Osterhaus A.D. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol 76 (2002) 11561
40. De Waal L., Power U.F., Yuksel S., Van Amerongen G., Nguyen T.N., Niesters H.G., De Swart R.L., and Osterhaus A.D. Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine 22 (2004) 915
41. De Waal L., Wyatt L.S., Yuksel S., Van Amerongen G., Moss B., Niesters H.G., Osterhaus A.D., and De Swart R.L. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine 22 (2004) 923
42. Delgado M.F., and Polack F.P. Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease. Expert Rev Vaccines 3 (2004) 693
43. Dollenmaier G., Mosier S.M., Scholle F., Sharma N., Mcknight K.L., and Lemon S.M. Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic. Virology 281 (2001) 216
44. Durbin A.P., and Karron R.A. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin Infect Dis 37 (2003) 1668
45. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., and Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352 (2005) 1749
46. Falsey A.R., and Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14 (1996) 1214
47. Falsey A.R., and Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 15 (1997) 1130
48. Fouillard L., Mouthon L., Laporte J.P., Isnard F., Stachowiak J., Aoudjhane M., Lucet J.C., Wolf M., Bricourt F., Douay L., Lopez M., Marche C., Najman A., and Gorin N.C. Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. Bone Marrow Transplant 9 (1992) 97
49. Friedewald W.T., Forsyth B.R., Smith C.B., Gharpure M.A., and Chanock R.M. Low-temperature-grown RS virus in adult volunteers. JAMA 203 (1968) 690
50. Garcia-Barreno B., Palomo C., Penas C., Delgado T., Perez-Brena P., and Melero J.A. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol 63 (1989) 925
51. Gonzalez I.M., Karron R.A., Eichelberger M., Walsh E.E., Delagarza V.W., Bennett R., Chanock R.M., Murphy B.R., Clements-Mann M.L., and Falsey A.R. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 18 (2000) 1763
52. Groothuis J.R., King S.J., Hogerman D.A., Paradiso P.R., and Simoes E.A. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 177 (1998) 467
53. Gupta C.K., Leszczynski J., Gupta R.K., and Siber G.R. Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin [published erratum appears in Vaccine 1997; 15(2): 247]. Vaccine 14 (1996) 1417
54. Gutekunst R.R., White R.J., Edmondson W.P., and Chanock R.M. Immunization with live type 4 adenovirus: determination of infectious virus dose and protective effect of enteric infection. Am J Epidemiol 86 (1967) 341
55. Hancock G.E., Heers K.M., Pryharski K.S., Smith J.D., and Tiberio L. Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus. Vaccine 21 (2003) 4348
56. Hancock G.E., Speelman D.J., Frenchick P.J., Mineo-Kuhn M.M., Baggs R.B., and Hahn D.J. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine 13 (1995) 391
57. Harcourt J.L., Anderson L.J., Sullender W., and Tripp R.A. Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles. Vaccine 22 (2004) 2248
58. Henderson F.W., Collier A.M., Clyde Jr. W.A., and Denny F.W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 300 (1979) 530
59. Hendry R.M., Burns J.C., Walsh E.E., Graham B.S., Wright P.F., Hemming V.G., Rodriguez W.J., Kim H.W., Prince G.A., McIntosh K., Chanock R.M., and Murphy B.R. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis 157 (1988) 640
60. Hsu K.H., Lubeck M.D., Bhat B.M., Bhat R.A., Kostek B., Selling B.H., Mizutani S., Davis A.R., and Hung P.P. Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Vaccine 12 (1994) 607
61. Hsu K.H., Lubeck M.D., Davis A.R., Bhat R.A., Selling B.H., Bhat B.M., Mizutani S., Murphy B.R., Collins P.L., Chanock R.M., and Hung P.P. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J Infect Dis 166 (1992) 769
62. Hurwitz J.L., Soike K.F., Sangster M.Y., Portner A., Sealy R.E., Dawson D.H., and Coleclough C. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. Vaccine 15 (1997) 533
63. Hussell T., Baldwin C.J., O'garra A., and Openshaw P.J. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur J Immunol 27 (1997) 3341
64. Iqbal M., Lin W., Jabbal-Gill I., Davis S.S., Steward M.W., and Illum L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21 (2003) 1478
65. Ison M.G., Mills J., Openshaw P., Zambon M., Osterhaus A., and Hayden F. Current research on respiratory viral infections: Fourth International Symposium. Antiviral Res 55 (2002) 227
66. Jin H., Cheng X., Zhou H.Z., Li S., and Seddiqui A. Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents. J Virol 74 (2000) 74
67. Jin H., Clarke D., Zhou H.Z., Cheng X., Coelingh K., Bryant M., and Li S. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology 251 (1998) 206
68. Jin H., Zhou H., Cheng X., Tang R., Munoz M., and Nguyen N. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 273 (2000) 210
69. Johnson Jr. P.R., Olmsted R.A., Prince G.A., Murphy B.R., Alling D.W., Walsh E.E., and Collins P.L. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol 61 (1987) 3163
70. Johnson P.R., Spriggs M.K., Olmsted R.A., and Collins P.L. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci USA 84 (1987) 5625
71. Johnson T.R., Johnson J.E., Roberts S.R., Wertz G.W., Parker R.A., and Graham B.S. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol 72 (1998) 2871
72. Johnson T.R., Teng M.N., Collins P.L., and Graham B.S. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol 78 (2004) 6024
73. Juhasz K., Murphy B.R., and Collins P.L. The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination. J Virol 73 (1999) 5176
74. Juhasz K., Whitehead S.S., Boulanger C.A., Firestone C.Y., Collins P.L., and Murphy B.R. The two amino acid substitutions in the l protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine 17 (1999) 1416
75. Kahn J.S., Roberts A., Weibel C., Buonocore L., and Rose J.K. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75 (2001) 11079
76. Kahn J.S., Schnell M.J., Buonocore L., and Rose J.K. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 254 (1999) 81
77. Kakuk T.J., Soike K., Brideau R.J., Zaya R.M., Cole S.L., Zhang J.Y., Roberts E.D., Wells P.A., and Wathen M.W. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 167 (1993) 553
78. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., and Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89 (1969) 405
79. Karron R.A., Belshe R.B., Wright P.F., Thumar B., Burns B., Newman F., Cannon J.C., Thompson J., Tsai T., Paschalis M., Wu S.L., Mitcho Y., Hackell J., Murphy B.R., and Tatem J.M. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 22 (2003) 394
80. Karron R.A., Buonagurio D.A., Georgiu A.F., Whitehead S.S., Adamus J.E., Clements-Mann M.L., Harris D.O., Randolph V.B., Udem S.A., Murphy B.R., and Sidhu M.S. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci USA 94 (1997) 13961
81. Karron R.A., Wright P.F., Belshe R.B., Thumar B., Casey R., Newman F., Polack F.P., Randolph V.B., Deatly A., Hackell J., Gruber W., Murphy B.R., and Collins P.L. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 191 (2005) 1093
82. Karron R.A., Wright P.F., Crowe Jr. J.E., Clements M.L., Thompson J., Makhene M., Casey R., and Murphy B.R. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, adults, infants and children. J Infect Dis 176 (1997) 1428
83. Kim H.W., Arrobio J.O., Pyles G., Brandt C.D., Camargo E., Chanock R.M., and Parrott R.H. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics 48 (1971) 745
84. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., and Parrott R.H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89 (1969) 422
85. Kim H.W., Leikin S.L., Arrobio J., Brandt C.D., Chanock R.M., and Parrott R.H. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 10 (1976) 75
86. Krempl C., Murphy B.R., and Collins P.L. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. J Virol 76 (2002) 11931
87. Kulkarni A.B., Collins P.L., Bacik I., Yewdell J.W., Bennink J.R., Crowe Jr. J.E., and Murphy B.R. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J Virol 69 (1995) 1261
88. Kumar M., Behera A.K., Lockey R.F., Zhang J., Bhullar G., De La Cruz C.P., Chen L.C., Leong K.W., Huang S.K., and Mohapatra S.S. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 13 (2002) 1415
89. Li X., Sambhara S., Li C.X., Ettorre L., Switzer I., Cates G., James O., Parrington M., Oomen R., Du R.P., and Klein M. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 269 (2000) 54
90. Li X., Sambhara S., Li C.X., Ewasyshyn M., Parrington M., Caterini J., James O., Cates G., Du R.P., and Klein M. Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med 188 (1998) 681
91. Lo M.S., Brazas R.M., and Holtzman M.J. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol 79 (2005) 9315
92. Mader D., Huang Y., Wang C., Fraser R., Issekutz A.C., Stadnyk A.W., and Anderson R. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge. Vaccine 18 (2000) 1110
93. Martin-Gallardo A., Fleischer E., Doyle S.A., Arumugham R., Collins P.L., Hildreth S.W., and Paradiso P.R. Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium. J Gen Virol 74 (1993) 453
94. Martinez F.D. Heterogeneity of the association between lower respiratory illness in infancy and subsequent asthma. Proc Am Thorac Soc 2 (2005) 157
95. Martinez-Sobrido L., Gitiban N., Fernandez-Sesma A., Cros J., Mertz S.E., Jewell N.A., Hammond S., Flano E., Durbin R.K., Garcia-Sastre A., and Durbin J.E. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol 80 (2006) 1130
96. Mcauliffe J.M., Surman S.R., Newman J.T., Riggs J.M., Collins P.L., Murphy B.R., and Skiadopoulos M.H. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro. J Virol 78 (2004) 2029
97. Mills J., Van Kirk J.E., Wright P.F., and Chanock R.M. Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol 107 (1971) 123
98. Munoz F.M., Piedra P.A., and Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21 (2003) 3465
99. Murphy B. Mucosal immunity to viruses. In: Mestecky J.E.A. (Ed). Mucosal Immunology (2005), Elsevier Academic Press, Amsterdam
100. Murphy B.R., Prince G.A., Collins P.L., Van Wyke Coelingh K., Olmsted R.A., Spriggs M.K., Parrott R.H., Kim H.W., Brandt C.D., and Chanock R.M. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res 11 (1988) 1
101. Murphy B.R., Prince G.A., Walsh E.E., Kim H.W., Parrott R.H., Hemming V.G., Rodriguez W.J., and Chanock R.M. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 24 (1986) 197
102. Murphy B.R., Sotnikov A., Paradiso P.R., Hildreth S.W., Jenson A.B., Baggs R.B., Lawrence L., Zubak J.J., Chanock R.M., Beeler J.A., and Prince G.A. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7 (1989) 533
103. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., and Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8 (1990) 497
104. Murphy B.R., and Walsh E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 26 (1988) 1595
105. Nicholas J.A., Rubino K.L., Levely M.E., Adams E.G., and Collins P.L. Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. J Virol 64 (1990) 4232
106. Nolan S.M., Surman S.R., Amaro-Carambot E., Collins P.L., Murphy B.R., and Skiadopoulos M.H. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Vaccine 23 (2005) 4765
107. Oien N.L., Brideau R.J., Walsh E.E., and Wathen M.W. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine 12 (1994) 731
108. Olmsted R.A., Buller R.M., Collins P.L., London W.T., Beeler J.A., Prince G.A., Chanock R.M., and Murphy B.R. Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus. Vaccine 6 (1988) 519
109. Oomens A.G., and Wertz G.W. The baculovirus GP64 protein mediates highly stable infectivity of a human respiratory syncytial virus lacking its homologous transmembrane glycoproteins. J Virol 78 (2004) 124
110. Openshaw P.J., and Tregoning J.S. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 18 (2005) 541
111. Paradiso P.R., Hildreth S.W., Hogerman D.A., Speelman D.J., Lewin E.B., Oren J., and Smith D.H. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J 13 (1994) 792
112. Piedra P.A., Cron S.G., Jewell A., Hamblett N., Mcbride R., Palacio M.A., Ginsberg R., Oermann C.M., and Hiatt P.W. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 21 (2003) 2448
113. Piedra P.A., Grace S., Jewell A., Spinelli S., Bunting D., Hogerman D.A., Malinoski F., and Hiatt P.W. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 15 (1996) 23
114. Piedra P.A., Grace S., Jewell A., Spinelli S., Hogerman D.A., Malinoski F., and Hiatt P.W. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J 17 (1998) 217
115. Plotnicky-Gilquin H., Cyblat-Chanal D., Aubry J.P., Champion T., Beck A., Nguyen T., Bonnefoy J.Y., and Corvaia N. Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment. J Virol 76 (2002) 10203
116. Plotnicky-Gilquin H., Huss T., Aubry J.P., Haeuw J.F., Beck A., Bonnefoy J.Y., Nguyen T.N., and Power U.F. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virology 258 (1999) 128
117. Plotnicky-Gilquin H., Robert A., Chevalet L., Haeuw J.F., Beck A., Bonnefoy J.Y., Brandt C., Siegrist C.A., Nguyen T.N., and Power U.F. CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment. J Virol 74 (2000) 3455
118. Polack F.P., Teng M.N., Collins P.L., Prince G.A., Exner M., Regele H., Lirman D.D., Rabold R., Hoffman S.J., Karp C.L., Kleeberger S.R., Wills-Karp M., and Karron R.A. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 196 (2002) 859
119. Power U.F., Nguyen T.N., Rietveld E., De Swart R.L., Groen J., Osterhaus A.D., De Groot R., Corvaia N., Beck A., Bouveret-Le-Cam N., and Bonnefoy J.Y. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 184 (2001) 1456
120. Power U.F., Plotnicky-Gilquin H., Huss T., Robert A., Trudel M., St∼Ahl S., Uhlen M., Nguyen T.N., and Binz H. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 230 (1997) 155
121. Prince G.A., Capiau C., Deschamps M., Fabry L., Garcon N., Gheysen D., Prieels J.P., Thiry G., Van Opstal O., and Porter D.D. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J Virol 74 (2000) 10287
122. Prince G.A., Curtis S.J., Yim K.C., and Porter D.D. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82 (2001) 2881
123. Prince G.A., Denamur F., Deschamps M., Garcon N., Prieels J.P., Slaoui M., Thiriart C., and Porter D.D. Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine 19 (2001) 2048
124. Prince G.A., Hemming V.G., Horswood R.L., Baron P.A., and Chanock R.M. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol 61 (1987) 1851
125. Prince G.A., Horswood R.L., Camargo E., Suffin S.C., and Chanock R.M. Parenteral immunization with live respiratory syncytial virus is blocked in seropositive cotton rats. Infect Immun 37 (1982) 1074
126. Prince G.A., Horswood R.L., and Chanock R.M. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 55 (1985) 517
127. Prince G.A., Jenson A.B., Hemming V.G., Murphy B.R., Walsh E.E., Horswood R.L., and Chanock R.M. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol 57 (1986) 721
128. Prince G.A., Mond J.J., Porter D.D., Yim K.C., Lan S.J., and Klinman D.M. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol 77 (2003) 13156
129. Prince G.A., Potash L., Horswood R.L., Camargo E., Suffin S.C., Johnson R.A., and Chanock R.M. Intramuscular inoculation of live respiratory syncytial virus induces immunity in cotton rats. Infect Immun 23 (1979) 723
130. Pringle C.R., Filipiuk A.H., Robinson B.S., Watt P.J., Higgins P., and Tyrrell D.A. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 11 (1993) 473
131. Ramaswamy M., Shi L., Monick M.M., Hunninghake G.W., and Look D.C. Specific inhibition of type I interferon signal transduction by respiratory syncytial virus. Am J Respir Cell Mol Biol 30 (2004) 893
132. Regner M., Culley F., Fontannaz P., Hu K., Morein B., Lambert P.H., Openshaw P., and Siegrist C.A. Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunisation against respiratory syncytial virus infection. Microbes Infect 6 (2004) 666
133. Rodriguez W.J., Gruber W.C., Groothuis J.R., Simoes E.A., Rosas A.J., Lepow M., Kramer A., and Hemming V. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 100 (1997) 937
134. Sandhu J.S., Krasnyanski S.F., Domier L.L., Korban S.S., Osadjan M.D., and Buetow D.E. Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response. Transgenic Res 9 (2000) 127
135. Schmidt A.C., Mcauliffe J.M., Murphy B.R., and Collins P.L. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol 75 (2001) 4594
136. Schmidt A.C., Wenzke D.R., Mcauliffe J.M., St. Clair M., Elkins W.R., Murphy B.R., and Collins P.L. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol 76 (2002)
137. Shay D.K., Holman R.C., Newman R.D., Liu L.L., Stout J.W., and Anderson L.J. Bronchiolitis-associated hospitalizations among US children, 1980-1996. J Am Med Assoc 282 (1999) 1440
138. Siegrist C.A., Barrios C., Martinez X., Brandt C., Berney M., Cordova M., Kovarik J., and Lambert P.H. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur J Immunol 28 (1998) 4138
139. Skiadopoulos M.H., Biacchesi S., Buchholz U.J., Riggs J.M., Surman S.R., Amaro-Carambot E., Mcauliffe J.M., Elkins W.R., St Claire M., Collins P.L., and Murphy B.R. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 78 (2004) 6927
140. Skiadopoulos M.H., Surman S.R., Riggs J.M., Elkins W.R., St Claire M., Nishio M., Garcin D., Kolakofsky D., Collins P.L., and Murphy B.R. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology 297 (2002) 153
141. Skiadopoulos M.H., Surman S.R., Riggs J.M., Orvell C., Collins P.L., and Murphy B.R. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology 297 (2002) 136
142. Slobod K.S., Shenep J.L., Lujan-Zilbermann J., Allison K., Brown B., Scroggs R.A., Portner A., Coleclough C., and Hurwitz J.L. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 22 (2004) 3182
143. Spann K.M., Tran K.C., Chi B., Rabin R.L., and Collins P.L. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophage. J Virol 78 (2004) 4363
144. Spann K.M., Tran K.C., and Collins P.L. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol 79 (2005) 5353
145. Srikiatkhachorn A., and Braciale T.J. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 186 (1997) 421
146. Takimoto T., Hurwitz J.L., Coleclough C., Prouser C., Krishnamurthy S., Zhan X., Boyd K., Scroggs R.A., Brown B., Nagai Y., Portner A., and Slobod K.S. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J Virol 78 (2004) 6043
147. Takimoto T., Hurwitz J.L., Zhan X., Krishnamurthy S., Prouser C., Brown B., Coleclough C., Boyd K., Scroggs R.A., Portner A., and Slobod K.S. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol 18 (2005) 255
148. Tang R.S., Macphail M., Schickli J.H., Kaur J., Robinson C.L., Lawlor H.A., Guzzetta J.M., Spaete R.R., and Haller A.A. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J Virol 78 (2004) 11198
149. Tang R.S., Nguyen N., Cheng X., and Jin H. Requirement of cysteines and length of the human respiratory syncytial virus m2-1 protein for protein function and virus viability. J Virol 75 (2001) 11328
150. Tang R.S., Nguyen N., Zhou H., and Jin H. Clustered charge-to-alanine mutagenesis of human respiratory syncytial virus L polymerase generates temperature-sensitive viruses. Virology 302 (2002) 207
151. Tang R.S., Schickli J.H., Macphail M., Fernandes F., Bicha L., Spaete J., Fouchier R.A., Osterhaus A.D., Spaete R., and Haller A.A. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′ proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol 77 (2003) 10819
152. Tang Y.W., and Graham B.S. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest 94 (1994) 1953
153. Tebbey P.W., Scheuer C.A., Peek J.A., Zhu D., Lapierre N.A., Green B.A., Phillips E.D., Ibraghimov A.R., Eldridge J.H., and Hancock G.E. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29 H. Vaccine 18 (2000) 2723
154. Teng M.N., and Collins P.L. The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo. J Virol 76 (2002) 6164
155. Teng M.N., Whitehead S.S., Bermingham A., Clair M.S., Elkins W.R., Murphy B.R., and Collins P.L. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 74 (2000) 9317
156. Teng M.N., Whitehead S.S., and Collins P.L. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 289 (2001) 283
157. Tolley K.P., Marriott A.C., Simpson A., Plows D.J., Matthews D.A., Longhurst S.J., Evans J.E., Johnson J.L., Cane P.A., Randolph V.B., Easton A.J., and Pringle C.R. Identification of mutations contributing to the reduced virulence of a modified strain of respiratory syncytial virus. Vaccine 14 (1996) 1637
158. Tripp R.A., Jones L.P., Haynes L.M., Zheng H., Murphy P.M., and Anderson L.J. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2 (2001) 732
159. Tristram D.A., Welliver R.C., Hogerman D.A., Hildreth S.W., and Paradiso P. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement. Vaccine 12 (1994) 551
160. Tristram D.A., Welliver R.C., Mohar C.K., Hogerman D.A., Hildreth S.W., and Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 167 (1993) 191
161. Trudel M., Nadon F., Seguin C., and Binz H. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology 185 (1991) 749
162. Trudel M., Stott E.J., Taylor G., Oth D., Mercier G., Nadon F., Seguin C., Simard C., and Lacroix M. Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection. Arch Virol 117 (1991) 59
163. Valarcher J.F., Furze J., Wyld S., Cook R., Conzelmann K.K., and Taylor G. Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J Virol 77 (2003) 8426
164. Vaughan K., Rhodes G.H., and Gershwin L.J. DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys. Vaccine 23 (2005) 2928
165. Walsh E.E. Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. J Infect Dis 170 (1994) 345
166. Walsh E.E., Hall C.B., Briselli M., Brandriss M.W., and Schlesinger J.J. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J Infect Dis 155 (1987) 1198
167. Waris M.E., Tsou C., Erdman D.D., Day D.B., and Anderson L.J. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J Virol 71 (1997) 6935
168. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., and Anderson L.J. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 70 (1996) 2852
169. Wathen M.W., Brideau R.J., and Thomsen D.R. Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein produced using a baculovirus vector. J Infect Dis 159 (1989) 255
170. Wathen M.W., Brideau R.J., Thomsen D.R., and Murphy B.R. Characterization of a novel human respiratory syncytial virus chimeric FG glycoprotein expressed using a baculovirus vector. J Gen Virol 70 (1989) 2625
171. Watt P.J., Robinson B.S., Pringle C.R., and Tyrrell D.A. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine 8 (1990) 231
172. Whitehead S.S., Bukreyev A., Teng M.N., Firestone C.Y., St Claire M., Elkins W.R., Collins P.L., and Murphy B.R. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol 73 (1999) 3438
173. Whitehead S.S., Firestone C.Y., Collins P.L., and Murphy B.R. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 247 (1998) 232
174. Whitehead S.S., Firestone C.Y., Karron R.A., Crowe Jr. J.E., Elkins W.R., Collins P.L., and Murphy B.R. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 73 (1999) 871
175. Whitehead S.S., Hill M.G., Firestone C.Y., St Claire M., Elkins W.R., Murphy B.R., and Collins P.L. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. J Virol 73 (1999) 9773
176. Whitehead S.S., Juhasz K., Firestone C.Y., Collins P.L., and Murphy B.R. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 72 (1998) 4467
177. World Health Organization Initiaitive for vaccine research: respiratory syncytial virus (RSV), 2005. http://www.who.int/vaccine_research/diseases/ari/en/index3.html.
178. Wright P.F., Karron R.A., Belshe R.B., Thompson J., Crowe Jr. J.E., Boyce T.G., Halburnt L.L., Reed G.W., Whitehead S.S., Anderson E.L., Wittek A.E., Casey R., Eichelberger M., Thumar B., Randolph V.B., Udem S.A., Chanock R.M., and Murphy B.R. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 182 (2000) 1331
179. Wright P.F., Karron R.A., Madhi S.A., Treanor J.J., King J.C., O'shea A., Ikizler M.R., Zhu Y., Collins P.L., Cutland C., Randolph V.B., Deatly A.M., Hackell J.G., Gruber W.C., and Murphy B. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis 193 (2006)
180. Wright P.F., Shinozaki T., Fleet W., Sell S.H., Thompson J., and Karzon D.T. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J Pediatr 88 (1976) 931
181. Wyatt L.S., Whitehead S.S., Venanzi K.A., Murphy B.R., and Moss B. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 18 (1999) 392
182. Yusibov V., Mett V., Mett V., Davidson C., Musiychuk K., Gilliam S., Farese A., Macvittie T., and Mann D. Peptide-based candidate vaccine against respiratory syncytial virus. Vaccine 23 (2005) 2261